Cargando…

Possible Anandamide and Palmitoylethanolamide involvement in human stroke

BACKGROUND: Endocannabinoids (eCBs) are ubiquitous lipid mediators that act on specific (CB1, CB2) and non-specific (TRPV1, PPAR) receptors. Despite many experimental animal studies proved eCB involvement in the pathogenesis of stroke, such evidence is still lacking in human patients. Our aim was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Naccarato, Marcello, Pizzuti, Daniela, Petrosino, Stefania, Simonetto, Marco, Ferigo, Laura, Grandi, Fabio Chiodo, Pizzolato, Gilberto, Di Marzo, Vincenzo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877050/
https://www.ncbi.nlm.nih.gov/pubmed/20470384
http://dx.doi.org/10.1186/1476-511X-9-47
_version_ 1782181754988134400
author Naccarato, Marcello
Pizzuti, Daniela
Petrosino, Stefania
Simonetto, Marco
Ferigo, Laura
Grandi, Fabio Chiodo
Pizzolato, Gilberto
Di Marzo, Vincenzo
author_facet Naccarato, Marcello
Pizzuti, Daniela
Petrosino, Stefania
Simonetto, Marco
Ferigo, Laura
Grandi, Fabio Chiodo
Pizzolato, Gilberto
Di Marzo, Vincenzo
author_sort Naccarato, Marcello
collection PubMed
description BACKGROUND: Endocannabinoids (eCBs) are ubiquitous lipid mediators that act on specific (CB1, CB2) and non-specific (TRPV1, PPAR) receptors. Despite many experimental animal studies proved eCB involvement in the pathogenesis of stroke, such evidence is still lacking in human patients. Our aim was to determine eCB peripheral levels in acute stroke patients and evaluate their relationship with clinical disability and stroke volume. METHODS: A cohort of ten patients with a first acute (within six hours since symptoms onset) ischemic stroke and a group of eight age- and sex-matched normal subjects were included. Groups were also matched for metabolic profile. All subjects underwent a blood sample collection for anandamide (AEA), 2-arachidonoylglycerol (2-AG) and palmitoylethanolamide (PEA) measurement; blood sampling was repeated in patients on admission (T0), at 6 (T1) and 18 hours (T2) thereafter. Patients neurological impairment was assessed using NIHSS and Fugl-Meyer Scale arm subitem (FMSa); stroke volume was determined on 48 h follow-up brain CT scans. Blood samples were analyzed by liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. RESULTS: 1)T0 AEA levels were significantly higher in stroke patients compared to controls. 2)A significant inverse correlation between T0 AEA levels and FMSa score was found. Moreover a positive correlation between T0 AEA levels and stroke volume were found in stroke patients. T0 PEA levels in stroke patients were not significantly different from the control group, but showed a significant correlation with the NIHSS scores. T0 2-AG levels were lower in stroke patients compared to controls, but such difference did not reach the significance threshold. CONCLUSIONS: This is the first demonstration of elevated peripheral AEA levels in acute stroke patients. In agreement with previous murine studies, we found a significant relationship between AEA or PEA levels and neurological involvement, such that the greater the neurological impairment, the higher were these levels.
format Text
id pubmed-2877050
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28770502010-05-27 Possible Anandamide and Palmitoylethanolamide involvement in human stroke Naccarato, Marcello Pizzuti, Daniela Petrosino, Stefania Simonetto, Marco Ferigo, Laura Grandi, Fabio Chiodo Pizzolato, Gilberto Di Marzo, Vincenzo Lipids Health Dis Research BACKGROUND: Endocannabinoids (eCBs) are ubiquitous lipid mediators that act on specific (CB1, CB2) and non-specific (TRPV1, PPAR) receptors. Despite many experimental animal studies proved eCB involvement in the pathogenesis of stroke, such evidence is still lacking in human patients. Our aim was to determine eCB peripheral levels in acute stroke patients and evaluate their relationship with clinical disability and stroke volume. METHODS: A cohort of ten patients with a first acute (within six hours since symptoms onset) ischemic stroke and a group of eight age- and sex-matched normal subjects were included. Groups were also matched for metabolic profile. All subjects underwent a blood sample collection for anandamide (AEA), 2-arachidonoylglycerol (2-AG) and palmitoylethanolamide (PEA) measurement; blood sampling was repeated in patients on admission (T0), at 6 (T1) and 18 hours (T2) thereafter. Patients neurological impairment was assessed using NIHSS and Fugl-Meyer Scale arm subitem (FMSa); stroke volume was determined on 48 h follow-up brain CT scans. Blood samples were analyzed by liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. RESULTS: 1)T0 AEA levels were significantly higher in stroke patients compared to controls. 2)A significant inverse correlation between T0 AEA levels and FMSa score was found. Moreover a positive correlation between T0 AEA levels and stroke volume were found in stroke patients. T0 PEA levels in stroke patients were not significantly different from the control group, but showed a significant correlation with the NIHSS scores. T0 2-AG levels were lower in stroke patients compared to controls, but such difference did not reach the significance threshold. CONCLUSIONS: This is the first demonstration of elevated peripheral AEA levels in acute stroke patients. In agreement with previous murine studies, we found a significant relationship between AEA or PEA levels and neurological involvement, such that the greater the neurological impairment, the higher were these levels. BioMed Central 2010-05-14 /pmc/articles/PMC2877050/ /pubmed/20470384 http://dx.doi.org/10.1186/1476-511X-9-47 Text en Copyright ©2010 Naccarato et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Naccarato, Marcello
Pizzuti, Daniela
Petrosino, Stefania
Simonetto, Marco
Ferigo, Laura
Grandi, Fabio Chiodo
Pizzolato, Gilberto
Di Marzo, Vincenzo
Possible Anandamide and Palmitoylethanolamide involvement in human stroke
title Possible Anandamide and Palmitoylethanolamide involvement in human stroke
title_full Possible Anandamide and Palmitoylethanolamide involvement in human stroke
title_fullStr Possible Anandamide and Palmitoylethanolamide involvement in human stroke
title_full_unstemmed Possible Anandamide and Palmitoylethanolamide involvement in human stroke
title_short Possible Anandamide and Palmitoylethanolamide involvement in human stroke
title_sort possible anandamide and palmitoylethanolamide involvement in human stroke
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877050/
https://www.ncbi.nlm.nih.gov/pubmed/20470384
http://dx.doi.org/10.1186/1476-511X-9-47
work_keys_str_mv AT naccaratomarcello possibleanandamideandpalmitoylethanolamideinvolvementinhumanstroke
AT pizzutidaniela possibleanandamideandpalmitoylethanolamideinvolvementinhumanstroke
AT petrosinostefania possibleanandamideandpalmitoylethanolamideinvolvementinhumanstroke
AT simonettomarco possibleanandamideandpalmitoylethanolamideinvolvementinhumanstroke
AT ferigolaura possibleanandamideandpalmitoylethanolamideinvolvementinhumanstroke
AT grandifabiochiodo possibleanandamideandpalmitoylethanolamideinvolvementinhumanstroke
AT pizzolatogilberto possibleanandamideandpalmitoylethanolamideinvolvementinhumanstroke
AT dimarzovincenzo possibleanandamideandpalmitoylethanolamideinvolvementinhumanstroke